Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to -$64000.0.

  • Envoy Medical's Gains from Investment Securities fell 12057.88% to -$64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$844000.0, marking a year-over-year increase of 3079.26%. This contributed to the annual value of $2.2 million for FY2024, which is 622.22% up from last year.
  • As of Q3 2025, Envoy Medical's Gains from Investment Securities stood at -$64000.0, which was down 12057.88% from -$37000.0 recorded in Q2 2025.
  • In the past 5 years, Envoy Medical's Gains from Investment Securities ranged from a high of $2.1 million in Q2 2024 and a low of -$14.4 million during Q1 2022
  • For the 4-year period, Envoy Medical's Gains from Investment Securities averaged around -$1.3 million, with its median value being -$64000.0 (2022).
  • Over the last 5 years, Envoy Medical's Gains from Investment Securities had its largest YoY gain of 197142.86% in 2024, and its largest YoY loss of 150000.0% in 2024.
  • Envoy Medical's Gains from Investment Securities (Quarter) stood at -$64000.0 in 2022, then skyrocketed by 135.94% to $23000.0 in 2023, then crashed by 1500.0% to -$322000.0 in 2024, then skyrocketed by 80.12% to -$64000.0 in 2025.
  • Its Gains from Investment Securities was -$64000.0 in Q3 2025, compared to -$37000.0 in Q2 2025 and -$421000.0 in Q1 2025.